These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16288496

  • 1. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
    Yurkovetsky ZR, Shurin GV, Barry DA, Schuh AC, Shurin MR, Robbins PD.
    J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
    [Abstract] [Full Text] [Related]

  • 2. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH.
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [Abstract] [Full Text] [Related]

  • 3. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y, Xia D, Li F, Zheng C, Xiang J.
    Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y, Zhang X, Zhang W, Chen Z, Chan T, Ali K, Jia Z, Xiang J.
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M, Andarini S, Zaini J, Xin H, Kanehira M, Suzuki T, Fukuhara T, Mizuguchi H, Hayakawa T, Saijo Y, Nukiwa T, Kikuchi T.
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [Abstract] [Full Text] [Related]

  • 6. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T, Miyazawa N, Moore MA, Crystal RG.
    Cancer Res; 2000 Nov 15; 60(22):6391-5. PubMed ID: 11103803
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy.
    Wu JQ, Zhao WH, Li Y, Zhu B, Yin KS.
    Virology; 2007 Nov 25; 368(2):309-16. PubMed ID: 17675129
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
    Tanaka F, Hashimoto W, Robbins PD, Lotze MT, Tahara H.
    Gene Ther; 2002 Nov 25; 9(21):1480-6. PubMed ID: 12378411
    [Abstract] [Full Text] [Related]

  • 11. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM, Mahtabifard A, Yamada R, Crystal RG, Korst RJ.
    Clin Cancer Res; 2002 Nov 25; 8(11):3561-9. PubMed ID: 12429647
    [Abstract] [Full Text] [Related]

  • 12. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
    Tolba KA, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ, Rosenblatt JD.
    Cancer Res; 2002 Nov 15; 62(22):6545-51. PubMed ID: 12438249
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
    Alvarez E, Moga E, Barquinero J, Sierra J, Briones J.
    Gene Ther; 2010 Apr 15; 17(4):469-77. PubMed ID: 20010627
    [Abstract] [Full Text] [Related]

  • 15. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.
    Bereta M, Bereta J, Park J, Medina F, Kwak H, Kaufman HL.
    Cancer Gene Ther; 2004 Dec 15; 11(12):808-18. PubMed ID: 15359290
    [Abstract] [Full Text] [Related]

  • 16. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
    Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W, Lynch DH.
    J Immunol; 1999 Aug 01; 163(3):1289-97. PubMed ID: 10415026
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
    Ishii S, Hiroishi K, Eguchi J, Hiraide A, Imawari M.
    Gene Ther; 2006 Jan 01; 13(1):78-87. PubMed ID: 16107857
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses.
    Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Jiang B, Chen H.
    Cancer Lett; 2010 Jul 28; 293(2):254-62. PubMed ID: 20149524
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.